Routine immunization profile: Lithuania

Routine immunization profile Lithuania Progress towards achieving European Vaccine Action Plan goals, 2017 Goal Indicator Status Goal Indicator Status 1 Sustain polio-free status a (Current risk) Yes (Low) 4 Meets vaccination coverage targets DTP3 national immunization coverage ≥95%d ≥90% DTP3 coverage achieved in ≥90% of districtse No No No 2 Measles elimination statusb Eliminated 5 Make evidence-based decisions about introduction of new vaccines*e NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV Yes Yes Yes YesRubella elimination status b Eliminated 3 Control hepatitis B infectionc Validation pending 6 Achieve financial sustainability of the national immunization programme**c Yes *New vaccines introduced or not introduced based on NITAG evidence-based recommendations **Country self-sufficient for procuring routine vaccines Demographic, income and health expenditure summary, 2017 Total Populationf 2 890 297 Live births 30 843 Surviving infants 30 727 <5 years 151 913 <15 years 428 435 Neonatal mortality rate (per 1000 live births)f 2 Infant mortality rate (per 1000 live births)f 3.4 Number of districtse 60 GNI (per capita, in USD)g ND Health spending as % of total government expenditureg 12 Immunization schedule, 2017e Birth BCG, HepB_Pediatric 1M HepB_Pediatric 2M DTaPHibIPV, PCV 4M DTaPHibIPV, PCV 6M DTaPHibIPV, HepB_Pediatric 12-15M PCV 15-16M MMR 18M DTaPHibIPV 6-7Y DTaPIPV, MMR 11Y HPV (2x) 15-16Y Tdap Routine immunization profile Lithuania Vaccine coverage estimates, 2013-2017d Number of reported cases of vaccine- preventable diseases, 2013-2017e 2013 2014 2015 2016 2017 Measles 35 11 50 22 2 Mumps 67 45 39 53 45 Rubella 2 0 0 0 0 Congenital rubella syndrome 0 0 0 0 0 Diphtheria 0 0 0 0 0 Tetanus 2 1 2 2 3 Pertussis 65 143 60 36 21 Hepatitis A 64 17 7 17 57 Varicella 14 738 22 311 15 294 13 604 16 005 DTP3 reported coverage by subnational area†, 2017e MCV2 reported coverage by subnational area†, 2017eMCV1 reported coverage by subnational area†, 2017e Surveillance with laboratory confirmation of cases, 2017e Measles Yes Rubella Yes Congenital rubella syndrome Yes Rotavirus Yes Invasive meningococcal disease Yes Invasive pneumococcal disease Yes Invasive Haemophilus influenzae disease Yes Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive Haemophilus influenzae disease. ≥95% 90-94% 80-89% <80% ND ≥95% 90-94% 80-89% <80% ND ≥95% 90-94% 80-89% <80% ND ND NR50 0100 2013 2014 2015 2016 2017 BCG 98 98 97 98 97 HepB-BD 98 97 97 97 97 DTP1 97 97 97 97 97 DTP3 93 93 93 94 94 HepB3 93 94 94 95 94 Hib3 93 93 93 94 94 Pol3 93 93 93 94 94 PCV3 NR NR ND 82 82 Rotac NR NR NR NR NR RCV1 93 93 94 94 94 MCV1 93 93 94 94 94 MCV2 92 92 92 92 92 Routine immunization profile Lithuania Number of reported measles, mumps and rubella casese and MCV coverage estimatesd, 2013-2017 DTP1-DTP3 dropout rate, 2013-2017d Note: Dropout rate is calculated using WUENIC Reported target population, reported number of DTP3 doses administered and DTP3 reported coveragee, 2013-2017 Number of reported diphtheria, tetanus and pertussis casese and DTP3 coverage estimatesd, 2013-2017 Percentage of districts by DTP3 reported coveragee, 2013-2017 Immunization system characteristics, 2017 Sustained access to WHO accredited polio, measles, and rubella laboratoriesh Yes NITAG in place that meets six WHO criteriae Yes National system in place to monitor AEFIse Yes Communication plan in place to respond to vaccine safety-related eventse No Vaccine hesitancy assessment performed within last 5 years e No Mandatory proof of immunization at school entrye No Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest 4 4 4 3 3 0 1 2 3 4 5 2013 2014 2015 2016 2017 DTP1-DTP3 dropout rate (%) Ye ar 0 20 40 60 80 100 0 5000 10000 15000 20000 25000 30000 35000 2013 2014 2015 2016 2017 % c ov er ag e N um be r Year DTP3 reported population DTP3 reported doses DTP3 reported coverage 79 78 90 90 88 19 18 8 8 10 2 3 2 2 2 0 20 40 60 80 100 2013 2014 2015 2016 2017 Percentage of subnational areas Ye ar ≥90% 80-89% 50-79% <50% ND 0 20 40 60 80 100 0 10 20 30 40 50 60 70 80 2013 2014 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Measles Mumps Rubella MCV1 coverage MCV2 coverage 0 20 40 60 80 100 0 20 40 60 80 100 120 140 160 2013 2014 2015 2016 2017 % c ov er ag e Nu m be r o f c as es Year Diptheria Tetanus Pertussis DTP3 coverage Note: Dropout rate is calculated using WUENIC Routine immunization profile Lithuania Vaccine stockouts by administrative levele, 2013-2017 Abbreviations Data sources *Data on HPV stockouts have only been collected in JRF since 2016 a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC c European Vaccine Action Plan 2015-2020 Midterm report d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring_surveillance/data/en/) e WHO/UNICEF Joint Reporting Form on immunization (JRF) f World Population Prospects: The 2017 Revision, New York, United Nations g World Bank, World Development Indicators h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network † The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map disclaimer AEFI Adverse event following immunization MCV1 measles-mumps-rubella vaccine, first dose BCG Bacille Calmette-Guerin vaccine for tuberculosis MCV2 measles-mumps-rubella vaccine, second dose CRS congenital Rubella Syndrome MMR measles-mumps-rubella vaccine DT diptheria-tetanus-containing vaccine ND Data not available DTP diptheria-tetanus-pertussis-containing vaccine NITAG National Immunization Technical Advisory Group DTP1 diphtheria-tetanus-pertussis-containing vaccine, first dose NR Not relevant as vaccine not included in immunization schedule DTP3 diphtheria-tetanus-pertussis-containing vaccine, third dose OPV oral polio vaccine GNI Gross national income PCV pneumococcal conjugate vaccine HepB hepatitis B PCV3 pneumococcal conjugate vaccine , third dose HepB3 hepatitis B vaccine, third dose Pol3 polio-containing vaccine, third dose HepB-BD hepatitis B vaccine, birth dose RCV1 rubella-containing vaccine, first dose Hib Haemophilus influenzae type b Rotac rotavirus vaccine-complete series Hib3 Haemophilus influenzae type b vaccine, third dose Td tetanus-diphtheria-containing vaccine HPV human papillomavirus TT tetanus toxoid vaccine IPV inactivated polio vaccine W,M,Y Weeks, Months, Years MCV measles-containing vaccine No stockout Subnational level stockout only National level stockout only Stockout at both levels NR ND 2013 2014 2015 2016 2017 BCG No No No No No DTP No No No No No HepB No No No No No Hib No No No No No Pneumo ND No No No No Rota NR NR NR NR NR OPV NR NR NR NR NR IPV No No No No No Measles No No No No No HPV * * * No Subnational TT ND ND ND ND ND ©World Health Organization 2019